Home ETF List About

Portfolio Holdings Detail for ISIN IE00BFNM3G45
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerSASU(USD) LSE
ETF TickerGPSA(GBP) LSE
ETF TickerSGAS(EUR) F
ETF TickerGPSA.LS(GBP) CXE
ETF TickerSASU.LS(USD) CXE
ETF TickerSASUz(USD) CXE
ETF TickerSGAS.DE(EUR) CXE
ETF TickerSASU.L(GBP) LSE
ETF TickerGPSA.L(GBP) LSE

Holdings detail for ALNY

Stock NameAlnylam Pharmaceuticals Inc
TickerALNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS02043Q1076
LEI529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI USA ESG Screened UCITS ETF USD (Acc) ALNY holdings

DateNumber of ALNY Shares HeldBase Market Value of ALNY SharesLocal Market Value of ALNY SharesChange in ALNY Shares HeldChange in ALNY Base ValueCurrent Price per ALNY Share HeldPrevious Price per ALNY Share Held
2025-09-29 (Monday)38,575USD 17,261,927USD 17,261,927
2025-09-26 (Friday)38,423USD 17,152,027USD 17,152,027
2025-09-25 (Thursday)38,079ALNY holding increased by 24USD 17,119,557ALNY holding decreased by -323713USD 17,119,55724USD -323,713 USD 449.58 USD 458.37
2025-09-24 (Wednesday)38,055USD 17,443,270USD 17,443,270
2025-09-18 (Thursday)37,599ALNY holding increased by 96USD 17,001,140ALNY holding increased by 60097USD 17,001,14096USD 60,097 USD 452.17 USD 451.725
2025-09-17 (Wednesday)37,503ALNY holding increased by 120USD 16,941,043ALNY holding decreased by -301492USD 16,941,043120USD -301,492 USD 451.725 USD 461.24
2025-09-16 (Tuesday)37,383ALNY holding increased by 192USD 17,242,535ALNY holding increased by 92277USD 17,242,535192USD 92,277 USD 461.24 USD 461.14
2025-09-15 (Monday)37,191ALNY holding increased by 64USD 17,150,258ALNY holding decreased by -146840USD 17,150,25864USD -146,840 USD 461.14 USD 465.89
2025-09-12 (Friday)37,127USD 17,297,098ALNY holding decreased by -99872USD 17,297,0980USD -99,872 USD 465.89 USD 468.58
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BFNM3G45

Show aggregate share trades of ALNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY24 449.580* 285.73
2025-09-18BUY96 452.170* 284.87
2025-09-17BUY120 451.725* 284.00
2025-09-16BUY192 461.240* 283.07
2025-09-15BUY64 461.140* 282.13
2025-09-11SELL-8 468.580* 280.16 Profit of 2,241 on sale
2025-08-15BUY16 448.910* 278.30
2025-08-13BUY8 432.520* 277.47
2025-07-31BUY40 392.240* 276.01
2025-07-29BUY160 330.550* 275.36
2025-07-28BUY32 324.790* 275.08
2025-07-25BUY48 328.810* 274.78
2025-07-24BUY24 328.000* 274.48
2025-07-23BUY56 325.640* 274.19
2025-07-22BUY32 325.280* 273.90
2025-07-18BUY64 320.530* 273.37
2025-07-17BUY48 324.690* 273.07
2025-07-11BUY64 314.940* 272.05
2025-07-10BUY72 322.640* 271.75
2025-07-09BUY72 320.870* 271.46
2025-07-07SELL-48 324.130* 270.86 Profit of 13,001 on sale
2025-07-02SELL-200 329.770* 269.74 Profit of 53,948 on sale
2025-06-27BUY24 322.830* 269.06
2025-06-26BUY24 318.250* 268.75
2025-06-24SELL-112 325.000* 268.05 Profit of 30,022 on sale
2025-06-18BUY64 312.320* 266.90
2025-06-17BUY24 308.710* 266.63
2025-06-16SELL-32 308.780* 266.35 Profit of 8,523 on sale
2025-06-13BUY72 307.990* 266.07
2025-06-12SELL-40 304.670* 265.81 Profit of 10,633 on sale
2025-06-11BUY88 298.580* 265.59
2025-06-06BUY24 300.830* 264.83
2025-06-05BUY112 308.000* 264.53
2025-06-04BUY16 305.310* 264.25
2025-06-03SELL-8 303.770* 263.97 Profit of 2,112 on sale
2025-05-30SELL-976 304.560* 263.38 Profit of 257,055 on sale
2025-05-29BUY24 292.900* 263.16
2025-05-27BUY136 290.100* 262.80
2025-05-23BUY120 289.960* 262.40
2025-05-22BUY56 289.000* 262.20
2025-05-19BUY48 291.860* 261.52
2025-05-16BUY24 285.310* 261.34
2025-05-15SELL-16 283.400* 261.17 Profit of 4,179 on sale
2025-05-14BUY8 267.550* 261.12
2025-05-13BUY16 266.860* 261.07
2025-05-12BUY56 270.190* 261.00
2025-05-09SELL-40 251.150* 261.08 Profit of 10,443 on sale
2025-05-08BUY16 258.350* 261.10
2025-05-07BUY24 276.550* 260.97
2025-05-02BUY888 259.390* 260.81
2025-04-30BUY280 263.240* 260.84
2025-04-29BUY72 257.190* 260.87
2025-04-28BUY56 254.850* 260.92
2025-04-25BUY144 251.560* 261.00
2025-04-24SELL-168 242.610* 261.16 Profit of 43,875 on sale
2025-04-23BUY152 241.970* 261.33
2025-04-22BUY64 236.750* 261.55
2025-04-17BUY88 234.560* 262.31
2025-04-15BUY80 230.930* 262.90
2025-04-11BUY128 237.770* 263.36
2025-04-09BUY48 243.270* 263.91
2025-04-08BUY288 224.320* 264.30
2025-04-07BUY96 232.950* 264.61
2025-04-04SELL-128 235.740* 264.90 Profit of 33,907 on sale
2025-04-02BUY1,088 266.830* 264.88
2025-04-01BUY8 255.760* 264.97
2025-03-31BUY56 270.020* 264.92
2025-03-28BUY32 268.460* 264.88
2025-03-27BUY16 271.020* 264.82
2025-03-26BUY8 269.210* 264.77
2025-03-25BUY88 280.960* 264.60
2025-03-24BUY104 290.700* 264.32
2025-03-21BUY96 283.340* 264.11
2025-03-19BUY24 253.440* 264.35
2025-03-18BUY288 244.300* 264.57
2025-03-17BUY56 253.110* 264.70
2025-03-14BUY416 241.760* 264.97
2025-03-13BUY80 241.750* 265.24
2025-03-12SELL-400 242.430* 265.52 Profit of 106,207 on sale
2025-03-11SELL-296 238.740* 265.84 Profit of 78,688 on sale
2025-03-10BUY88 233.070* 266.24
2025-03-07BUY16 244.520* 266.51
2025-03-05BUY120 249.230* 266.72
2025-03-04BUY136 242.930* 267.02
2025-03-03BUY256 243.530* 267.33
2025-02-28BUY208 246.750* 267.59
2025-02-27SELL-40 237.100* 267.99 Profit of 10,720 on sale
2025-02-25BUY296 245.200* 268.63
2025-02-21BUY32 250.590* 269.15
2025-02-18SELL-72 250.000* 269.96 Profit of 19,437 on sale
2025-02-14SELL-488 256.450* 270.37 Profit of 131,939 on sale
2025-02-13BUY8 264.890* 270.45
2025-02-12BUY80 265.960* 270.52
2025-02-07SELL-8 276.190* 270.39 Profit of 2,163 on sale
2025-02-06BUY152 278.250* 270.27
2025-02-05BUY40 276.310* 270.16
2025-02-04BUY48 271.000* 270.15
2025-02-03BUY48 274.550* 270.07
2025-01-31BUY88 271.310* 270.05
2025-01-29SELL-8 273.990* 269.85 Profit of 2,159 on sale
2025-01-28SELL-72 279.190* 269.68 Profit of 19,417 on sale
2025-01-27SELL-128 276.730* 269.55 Profit of 34,502 on sale
2025-01-24BUY96 278.760* 269.37
2025-01-23BUY16 275.540* 269.25
2024-12-10BUY400 253.910* 269.55
2024-12-09BUY48 255.890* 269.83
2024-12-06SELL-120 256.260* 270.12 Profit of 32,414 on sale
2024-12-05SELL-8 251.810* 270.51 Profit of 2,164 on sale
2024-12-03BUY40 251.840* 271.27
2024-11-27SELL-48 253.740* 273.02 Profit of 13,105 on sale
2024-11-26BUY168 253.350* 274.02
2024-11-26BUY168 253.350* 274.02
2024-11-25BUY1,929 250.980* 275.27
2024-11-25BUY1,929 250.980* 275.27
2024-11-22SELL-14 244.890* 276.11 Profit of 3,866 on sale
2024-11-21SELL-40 246.800* 276.95 Profit of 11,078 on sale
2024-11-20SELL-16 248.790* 277.78 Profit of 4,444 on sale
2024-11-19BUY8 234.270* 279.10
2024-11-18BUY72 232.270* 280.56
2024-11-11BUY24 279.820* 281.01
2024-11-11BUY24 279.820* 281.01
2024-11-07BUY20 272.220* 281.83
2024-11-07BUY20 272.220* 281.83
2024-11-06BUY192 273.010* 282.56
2024-11-06BUY192 273.010* 282.56
2024-11-05BUY40 265.290* 284.13
2024-11-05BUY40 265.290* 284.13
2024-11-04BUY14 269.950* 285.55
2024-11-04BUY14 269.950* 285.55
2024-11-01BUY21 273.910* 286.84
2024-11-01BUY21 273.910* 286.84
2024-10-30SELL-48 281.490* 290.50 Profit of 13,944 on sale
2024-10-30SELL-48 281.490* 290.50 Profit of 13,944 on sale
2024-10-29SELL-144 284.690* 291.47 Profit of 41,972 on sale
2024-10-29SELL-144 284.690* 291.47 Profit of 41,972 on sale
2024-10-28SELL-56 286.910* 292.38 Profit of 16,373 on sale
2024-10-28SELL-56 286.910* 292.38 Profit of 16,373 on sale
2024-10-21SELL-8 292.010* 0.00
2024-10-21SELL-8 292.010* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19216,7273,259396,24354.7%
2025-09-18172,875397386,43244.7%
2025-09-17246,547167472,29252.2%
2025-09-1688,84660226,33639.3%
2025-09-15148,25813,572435,68934.0%
2025-09-12134,122300244,96854.8%
2025-09-11219,8687,820411,70253.4%
2025-09-10543,3267,595916,89859.3%
2025-09-09705,54033,7311,550,89945.5%
2025-09-08175,158440388,71545.1%
2025-09-05127,116335311,25240.8%
2025-09-04110,9302,555236,56846.9%
2025-09-03182,3868,982562,92132.4%
2025-09-02132,77014,416358,47637.0%
2025-08-2993,2162,181276,59433.7%
2025-08-2860,1821,254226,86526.5%
2025-08-27277,6671,084440,57763.0%
2025-08-26243,404919447,42154.4%
2025-08-25156,55115,662374,27641.8%
2025-08-22228,5961,309408,15256.0%
2025-08-21123,9962,862248,30049.9%
2025-08-20149,63813,723316,98347.2%
2025-08-19144,3201,143308,39946.8%
2025-08-18371,31834,264525,78670.6%
2025-08-15104,01813,245265,62039.2%
2025-08-14133,2724,443505,52826.4%
2025-08-13183,2711,3901,017,62318.0%
2025-08-12173,0454,046693,01825.0%
2025-08-11239,1997,600451,24853.0%
2025-08-08168,7553,199466,74436.2%
2025-08-07308,8104,452527,39958.6%
2025-08-06202,15112,590548,34936.9%
2025-08-05256,29513,237826,28331.0%
2025-08-04411,11436,303729,94956.3%
2025-08-01350,06060,108764,94345.8%
2025-07-31829,1916,0231,541,01553.8%
2025-07-30533,88514,703942,78856.6%
2025-07-29164,26855384,53742.7%
2025-07-28150,24069571,96526.3%
2025-07-2590,782429298,80130.4%
2025-07-24132,00111,546286,15546.1%
2025-07-23184,14963312,34059.0%
2025-07-22134,7617,553524,61225.7%
2025-07-21113,303101243,11946.6%
2025-07-1884,1179196,31742.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.